After combining the two trials , the overall effect of reducing LDL-C with a statin-based regimen on vascular access occlusive events was not statistically significant ( @ -LSB- @ % -RSB- with any LDL-C-lowering therapy versus @ -LSB- @ % -RSB- with placebo ; RR , @ , @ % CI , @ to @ ; P = @ ) .